Author

Brian Köhn

Observed names: B Kohn, Brian Kohn

Institutions: London School of Hygiene & Tropical Medicine, Institut National de Santé Publique

Observed institutions: London School of Hygiene & Tropical Medicine, Mwanza Intervention Trials Unit, Institut National de Santé Publique, Janssen (Netherlands), National Institute for Medical Research

OpenAlex ID: A5013338197

Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial

2021 · Muhammed O Afolabi, David Ishola, et al. · The Lancet Infectious Diseases · 94

Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial

2021 · David Ishola, Daniela Manno, et al. · The Lancet Infectious Diseases · 93

Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases

2024 · Aurélie Wiedemann, Edouard Lhomme, et al. · Nature Communications · 23

Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults

2023 · Andrew W Lee, Ken Liu, et al. · Clinical Infectious Diseases · 19

Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone

2023 · Edward Man-Lik Choi, Boris Lacarra, et al. · The Lancet Global Health · 18

Asymptomatic Malaria Infection and the Immune Response to the 2-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen in Adults and Children

2022 · D Ishola, The EBOVAC-Salone Malaria Infection (MALI) Sub-Study Team, et al. · Clinical Infectious Diseases · 13

Ebola Virus Glycoprotein IgG Seroprevalence in Community Previously Affected by Ebola, Sierra Leone

2022 · Daniela Manno, Philip Ayieko, et al. · Emerging infectious diseases · 9

Evaluation of waning of IgG antibody responses after rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trial

2024 · Simon Valayer, Marie Alexandre, et al. · Emerging Microbes & Infections · 4

Need for Local Laboratory Reference Values in Recruitment into Studies of Emerging Infectious Diseases: Insight from Participant Screening for an Ebola Vaccine Trial in a Rural African Setting

2020 · David Ishola, Bailah Leigh, et al.

Works count: 11

Citation count: 460

H-index: 9

I10-index: 8